Reply to : Rong Dai and Changkai Deng’s Letter to the Editor re: Anirban Dey, Georgios Georgiadis, Justin Umezurike, et al. Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome—A Systematic Review. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2024.09.012. European Urology Focus

Dey, AnirbanGeorgiadis, GeorgiosUmezurike, JustinYuan, YuhongFarag, FawzyN'Dow, JamesOmar, Muhammad ImranMamoulakis, Charalampos2025-05-272025-05-272025-01-09Dey, A, Georgiadis, G, Umezurike, J, Yuan, Y, Farag, F, N'Dow, J, Omar, M I & Mamoulakis, C 2025, 'Reply to : Rong Dai and Changkai Deng’s Letter to the Editor re: Anirban Dey, Georgios Georgiadis, Justin Umezurike, et al. Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome—A Systematic Review. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2024.09.012. European Urology Focus', European Urology Focus. https://doi.org/10.1016/j.euf.2024.12.0042405-4569ORCID: /0000-0001-5340-0081/work/176746939ORCID: /0000-0002-1597-3126/work/176747587https://hdl.handle.net/2164/255132801396engR MedicineRReply to : Rong Dai and Changkai Deng’s Letter to the Editor re: Anirban Dey, Georgios Georgiadis, Justin Umezurike, et al. Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome—A Systematic Review. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2024.09.012. European Urology FocusJournal item10.1016/j.euf.2024.12.004